Phase 1 T-cell Lymphoma Clinical Trials
23 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 23 trials
Recruiting
Phase 1
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT06696846
Recruiting
Phase 1
CD4CAR for CD4+ Leukemia and Lymphoma
T-cell LymphomaT-cell Leukemia
Huda Salman20 enrolled6 locationsNCT03829540
Recruiting
Phase 1Phase 2
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
T-cell Lymphomas
Dizal Pharmaceuticals165 enrolled12 locationsNCT07496229
Recruiting
Phase 1Phase 2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Hodgkin LymphomaNon-Hodgkin LymphomaLymphoma+4 more
AstraZeneca161 enrolled33 locationsNCT06137144
Recruiting
Phase 1Phase 2
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
LGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell LymphomaPrimary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma+2 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting
Phase 1
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 1
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
T-cell Prolymphocytic LeukemiaT-cell LymphomasNK-Cell Lymphomas+1 more
Memorial Sloan Kettering Cancer Center70 enrolled9 locationsNCT05010005
Recruiting
Phase 1
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Refractory/Recurrent Peripheral T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07164560
Recruiting
Phase 1
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
T-cell Acute Lymphoblastic LeukemiaLymphoblastic T-Cell Lymphoma
OneChain Immunotherapeutics20 enrolled2 locationsNCT05679895
Recruiting
Phase 1Phase 2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Ovarian CancerMelanomaT-cell Lymphoma+1 more
BioInvent International AB176 enrolled25 locationsNCT04752826
Recruiting
Phase 1
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738
Recruiting
Phase 1Phase 2
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Haihe Biopharma Co., Ltd.100 enrolled1 locationNCT06909877
Recruiting
Phase 1
Q702 for the Treatment of Patients With Hematologic Malignancies
Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Phase 1
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
T-cell LymphomaCutaneous/Peripheral T-Cell Lymphoma
SciTech Development, Inc.46 enrolled10 locationsNCT04234048
Recruiting
Phase 1
Study of Tazemetostat in Lymphoid Malignancies
T-cell Lymphoma
University of Alabama at Birmingham30 enrolled1 locationNCT05983965
Recruiting
Phase 1
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Classical Hodgkin LymphomaExtranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Baylor College of Medicine18 enrolled2 locationsNCT04288726
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
Natural Killer/T-cell LymphomaRelapsed or Refractory Lymphoma Including ENKL
Fudan University68 enrolled1 locationNCT06966154
Recruiting
Phase 1Phase 2
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb85 enrolled40 locationsNCT06035497
Recruiting
Phase 1Phase 2
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Sun Yat-sen University33 enrolled1 locationNCT06855823
Recruiting
Phase 1Phase 2
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.95 enrolled1 locationNCT05934513